pubmed.ncbi.nlm.nih.gov

Flurbiprofen: A Nonselective Cyclooxygenase (COX) Inhibitor for Treatment of Noninfectious, Non-necrotizing Anterior Scleritis - PubMed

Flurbiprofen: A Nonselective Cyclooxygenase (COX) Inhibitor for Treatment of Noninfectious, Non-necrotizing Anterior Scleritis

Rupesh Agrawal et al. Ocul Immunol Inflamm. 2016.

Abstract

Objective: To analyze the safety and efficacy of a nonselective cyclo-oxygenase (COX) inhibitor in the management of noninfectious, non-necrotizing anterior scleritis.

Methods: Retrospective chart review of 126 patients with non-necrotizing anterior scleritis treated with oral flurbiprofen (Froben®(Abbott Healthcare)) with (Group B, n = 61) or without (Group A, n = 65) topical steroids was performed and time to remission was plotted.

Results: The observed incidence rate was 1.07 (95% CI: 0.57-1.99) per 1000 person-years with failure rate of 0.68 (95% CI: 0.22-2.12) per 1000 person-years in Group A and 1.41 (95% CI: 0.67-2.96) per 1000 person-years in Group B. The failure rate was 3.97 (1.89-9.34) per 1000 person-years with hazard ratio of 10.01 (95% CI: 2.52-39.65; p < 0.001) for patients with associated systemic disease.

Conclusion: To the of our best knowledge, this is the first and largest case series on the safety and efficacy of a nonselective COX inhibitor in the management of anterior scleritis.

Keywords: COX-inhibitor; flurbiprofen; froben; non-necrotizing scleritis; noninfective; oral NSAIDs.

PubMed Disclaimer

Conflict of interest statement

Competing interest: JJGL has received study grants from Alcon, Novartis and MSD, and has provided unpaid consultancy to Bayer. RA is on NMRC overseas research training fellowship at Institute of Ophthalmology and Moorfields Eye Hospital, London.

Figures

Figure 1
Figure 1

Figure 1A and 1B: Slit lamp photographs of the non-necrotising diffuse scleritis

Figure 2
Figure 2

Figure 2A: Scatter Plot of log values of Initial (Pre-treatment) visual acuity and Final (Post-treatment) visual acuity combined for both groups Figure 2B: Comparative scatter plot for both groups A and group B and scleritis patients with and without systemic disease

Figure 2
Figure 2

Figure 2A: Scatter Plot of log values of Initial (Pre-treatment) visual acuity and Final (Post-treatment) visual acuity combined for both groups Figure 2B: Comparative scatter plot for both groups A and group B and scleritis patients with and without systemic disease

Figure 3
Figure 3

Figure 3A: Overall kaplan Meir Survial graph Figure 3B: Kaplan-Meier survival estimates for group A and group B Figure 3C: Kaplan-Meier survival estimates by systemic disease association

Figure 3
Figure 3

Figure 3A: Overall kaplan Meir Survial graph Figure 3B: Kaplan-Meier survival estimates for group A and group B Figure 3C: Kaplan-Meier survival estimates by systemic disease association

Figure 3
Figure 3

Figure 3A: Overall kaplan Meir Survial graph Figure 3B: Kaplan-Meier survival estimates for group A and group B Figure 3C: Kaplan-Meier survival estimates by systemic disease association

Similar articles

Cited by

References

    1. Watson PG, Hayreh SS. Scleritis and episcleritis. The British journal of ophthalmology. 1976;60(3):163–191. - PMC - PubMed
    1. Sims J. Scleritis: presentations, disease associations and management. Postgraduate medical journal. 2012;88(1046):713–718. - PubMed
    1. Heron E, Gutzwiller-Fontaine M, Bourcier T. Scleritis and episcleritis: Diagnosis and treatment. La Revue de medecine interne/fondee ... par la Societe nationale francaise de medecine interne. 2014 - PubMed
    1. Katz MS, Chuck RS, Gritz DC. Scleritis and episcleritis. Ophthalmology. 2012;119(8):1715–1715. e1711. - PubMed
    1. Kirkwood BJ, Kirkwood RA. Episcleritis and scleritis. Insight. 2010;35(4):5–8. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources